Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 606752, 7 pages
http://dx.doi.org/10.1155/2015/606752
Clinical Study

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma

Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tiyuanbei, Huanhuxi Road, Hexi District, Tianjin 300060, China

Received 25 June 2014; Accepted 16 September 2014

Academic Editor: Shiwu Zhang

Copyright © 2015 Zhengzi Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. L. Zinzani, F. Venturini, V. Stefoni et al., “Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome,” Annals of Oncology, vol. 21, no. 4, pp. 860–863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Bai, H.-Q. Huang, Q.-Q. Cai et al., “Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma,” Medical Oncology, vol. 30, no. 1, p. 350, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. N. L. Bartlett, D. Niedzwiecki, J. L. Johnson et al., “Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804,” Annals of Oncology, vol. 18, no. 6, pp. 1071–1079, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Pileri, L. Leoncini, and B. Falini, “Revised European-American lymphoma classification,” Current Opinion in Oncology, vol. 7, no. 5, pp. 401–407, 1995. View at Google Scholar · View at Scopus
  5. B. D. Cheson, B. Pfistner, M. E. Juweid et al., “Revised response criteria for malignant lymphoma,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 579–586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Guglielmi, F. Gomez, T. Philip et al., “Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the parma trial,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3264–3269, 1998. View at Google Scholar · View at Scopus
  7. S. J. Kim, K. Kim, Y. Park et al., “Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity,” Investigational New Drugs, vol. 30, no. 1, pp. 368–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Lee, C. Suh, H. J. Kang et al., “Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma,” Annals of Oncology, vol. 19, no. 12, pp. 2079–2083, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. K. Ahn, S. J. Kim, D. W. Hwang et al., “Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma,” Investigational New Drugs, vol. 31, no. 2, pp. 469–472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Manegold, B. Bergman, A. Chemaissani et al., “Single-agent gemeitabine versus cisplatln-etoposlde: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer,” Annals of Oncology, vol. 8, no. 6, pp. 525–529, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. H. A. Burris III, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403–2413, 1997. View at Google Scholar · View at Scopus
  12. P. G. Rose, K. Mossbruger, N. Fusco, M. Smrekar, S. Eaton, and M. Rodriguez, “Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma,” Gynecologic Oncology, vol. 88, no. 1, pp. 17–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. L. Zinzani, G. Baliva, M. Magagnoli et al., “Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2603–2606, 2000. View at Google Scholar · View at Scopus
  14. E. Marchi, L. Alinari, M. Tani et al., “Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients,” Cancer, vol. 104, no. 11, pp. 2437–2441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Bergman, H. M. Pinedo, I. Talianidis et al., “Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines,” British Journal of Cancer, vol. 88, no. 12, pp. 1963–1970, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Bergman, B. Munch-Petersen, P. B. Jensen et al., “Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines,” Biochemical Pharmacology, vol. 61, no. 11, pp. 1401–1408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. C. H. Moskowitz, J. R. Bertino, J. R. Glassman et al., “Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 17, no. 12, pp. 3776–3785, 1999. View at Google Scholar · View at Scopus
  18. W. S. Velasquez, F. Cabanillas, P. Salvador et al., “Effective salvagae therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP),” Blood, vol. 71, no. 1, pp. 117–122, 1988. View at Google Scholar · View at Scopus
  19. F. Barlési, C. Doddoli, C. Gimenez, L. Greillier, G. Lima, and J.-P. Kleisbauer, “Acute pulmonary toxicity due to gemcitabine: a role for asbestos exposure?” Revue des Maladies Respiratoires, vol. 20, no. 2, part 1, pp. 201–206, 2003. View at Google Scholar · View at Scopus
  20. J. J. Castillo, D. Morales, P. Quinones, E. Cotrina, C. Desposorio, and B. Beltran, “Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified,” Leukemia and Lymphoma, vol. 51, no. 10, pp. 1822–1828, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. P. Escalón, N. S. Liu, Y. Yang et al., “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-T. Arkenau, G. Chong, D. Cunningham et al., “Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience,” Haematologica, vol. 92, no. 2, pp. 271–272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Xu, H. Wang, S. Zhou et al., “Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma,” Leukemia and Lymphoma, vol. 54, no. 7, pp. 1396–1404, 2013. View at Publisher · View at Google Scholar · View at Scopus